Clinical Trials in Spain

• Olaparib Monotherapy in HRRm or HRD Positive Cancer Ended
  2022-500797-34-00 Phase II Treatment of participants with positive cancer for HRRm or H… Merck Sharp & Dohme LLC
• A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in… Ended
  2024-512158-12-00 Phase III Bladder Cancer Muscle-Invasive Bladder Cancer Bristol-Myers Squibb Services Unlimited Company
• Combination of Talimogene Laherparepvec (modified Herpes Virus) with atezolizumab (monoclonal antibody) in patients with residual breast can… Ended
  2023-508550-25-00 Phase I (Other) Pre and post-menopausal women with resectable primary breast… Solti Group
• Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinoma Ended
  2023-508890-10-00 Phase III Gastric and gastric esophageal junction (GEJ) adenocarcinoma Merck Sharp & Dohme LLC
• Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib Ended
  2024-515040-23-00 Phase II Chronic Myelogenous Leukemia in chronic phase (CML-CP), prev… Novartis Pharma AG
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum… Ended
  2023-509061-20-00 Phase I/II Advanced solid tumors Bristol Myers Squibb International Corporation
• A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet… Ended
  2023-507312-13-00 Phase III Multiple Myeloma Janssen - Cilag International
• A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanc… Ended
  2024-515254-24-00 Phase I Previously treated lymphoma (blood cancer) or solid tumors a… Janssen Cilag International
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 Phase III Focal segmental glomerulosclerosis (FSGS) Travere Therapeutics Inc.
• A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv… Ended
  2023-508955-37-00 Phase III Moderate to severe atopic dermatitis Pfizer Inc.
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended
  2023-508253-98-00 Phase III Gastric or gastroesophageal junction (GEJ) adenocarcinoma Merck Sharp & Dohme LLC
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 Phase III Moderately to Severely Active Crohn's Disease Celgene International II SARL
• Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervi… Ended
  2024-514179-17-00 Phase III Metastatic (stage IVB), Persistent, or Recurrent Carcinoma o… Grupo Espanol De Investigacion En Cancer De Ovario
• Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended
  2023-510426-33-00 Phase III Moderately to Severely Active Crohn's Disease Celgene International II S.a.r.l.
• A Study Evaluating the Safety and Efficacy of KTE-X19 in pediatric and adolescent Subjects with Relapsed/Refractory B-precursor Acute Lympho… Ended
  2023-509440-97-00 Phase I (Other) Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia… Kite Pharma Inc.
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelia… Ended
  2024-517571-20-00 Phase III Locally advanced or metastatic urothelial cancer Astellas Pharma Global Development Inc.
• A Study to Assess Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small … Ended
  2023-508083-30-00 Phase II Non-small cell lung cancer (NSCLC) Genentech Inc.
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended
  2023-506641-35-00 Phase II Relapsed/Refractory Mantle Cell Lymphoma Kite Pharma Inc.
• A multicentre clinical trial: Alveolar bone augmentation using MSCs and biphasic calcium phosphate granules prior to dental implants (Behand… Ended
  2024-517976-39-00 Phase II/III Alveolar bone augmentation in patient with bone defects in j… University of Bergen
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended
  2023-508472-11-00 Phase III Patients with early breast cancer NSABP Foundation Inc.
• A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment … Ended
  2023-506564-14-00 Phase I Relapsed and refractory multiple myeloma (RRMM) Celgene International II S.a.r.l.
• A Study to Evaluate Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lu… Ended
  2023-504038-23-00 Phase I/II Metastatic non-small cell lung cancer (NSCLC) F. Hoffmann-La Roche AG
• PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStem Ended
  2022-500251-22-00 Phase II This study will include all patients having received at leas… Cellaïon SA
• A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not R… Ended
  2023-508727-12-00 Phase II Relapsed and refractory multiple myeloma (RRMM) Celgene Corp.

Showing 4,681–4,704 of 4,849 trials